Linked Life Data

12169240

Source:http://linkedlifedata.com/resource/pubmed/id/12169240

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2002-8-9
pubmed:abstractText
Beta-Adrenergic blockade is associated with a significant reduction in mortality in most patients with structural heart disease. Clinical trial data involving patients after myocardial infarction or with congestive heart failure demonstrate that a reduction in sudden death accounts for much of the observed mortality reduction. Beta-adrenergic blockade inhibits the proarrhythmic effects of both neural and humoral sympathetic stimulation and inhibits the vagal withdrawal that accompanies ischemia. Although it does not have a dramatic effect on spontaneous ectopy or inducible monomorphic ventricular tachycardia, experimental and clinical data suggest that it inhibits the development of ventricular fibrillation by several mechanisms.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1523-3782
pubmed:author
pubmed:issnType
Print
pubmed:volume
4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
426-33
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Beta-adrenergic blocking drugs as antifibrillatory agents.
pubmed:affiliation
Division of Cardiology, Box B-130, University of Colorado Health Sciences Center, 4200 East 9th Avenue, Denver, CO 80262, USA. Michael.Reiter@UCHSC.edu
pubmed:publicationType
Journal Article, Review